Aquestive Therapeutics (AQST) vs Sagimet Biosciences Series A (SGMT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Sagimet Biosciences Series A (SGMT) has outperformed Aquestive Therapeutics (AQST) over the past year, gaining 21.0% versus a loss of 22.6%. Sagimet Biosciences Series A is the larger company by market cap ($632.5 million vs $597.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AQST | SGMT |
|---|---|---|
| Share price | $4.76 | $8.92 |
| Market cap | $597.44M | $632.51M |
| 1-day change | +3.03% | +0.45% |
| YTD return | -28.48% | +50.00% |
| 1-year return | -22.61% | +20.98% |
| 5-year return | +19.38% | — |
| EPS (TTM) | $-0.66 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.55 | $11.45 |
| 52-week low | $2.93 | $4.50 |
| Distance from 52-week high | -36.95% | -22.09% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +96.01% | +212.89% |
| Average volume | 2.66M | 1.23M |
| Shares outstanding | 125.51M | 70.34M |
| Employees | 147 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SGMT has outperformed AQST by 43.6 percentage points over the past year.
About Aquestive Therapeutics
AQST stock →Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 147 employees
About Sagimet Biosciences Series A
SGMT stock →Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
AQST vs SGMT FAQ
Which is bigger, Aquestive Therapeutics or Sagimet Biosciences Series A?
Sagimet Biosciences Series A (SGMT) is larger, with a market capitalization of $632.51M compared with $597.44M for Aquestive Therapeutics (AQST).
Which stock has performed better over the past year, AQST or SGMT?
SGMT returned +20.98% over the past 12 months, compared with -22.61% for AQST (price return, excluding dividends). Past performance does not predict future results.
Are Aquestive Therapeutics and Sagimet Biosciences Series A in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.